Hematological Malignancies: Epidemiological, Clinical, Biological, Therapeutic and Evolutionary Aspects
American Journal of Laboratory Medicine
Volume 4, Issue 1, January 2019, Pages: 19-23
Received: Feb. 10, 2019; Accepted: Mar. 12, 2019; Published: Apr. 13, 2019
Views 83      Downloads 21
Authors
Mouhib Hanane, Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco
Zahir Hanane, Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco
Mouayche Ikhlas, Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco
Yahyaoui Hicham, Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco
Ait Ameur Mustapha, Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco
Chakour Mohammed, Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco
Article Tools
Follow on us
Abstract
Hematological malignancies are diseases, which include all cancers of blood and lymphoid organs. They result from a proliferation of mature blood cells or immature blood cells. However, in all cases, these blood cells escape the normal regulation. This work aims to determine the types and frequencies of diagnosed malignancies. It’s supported by the clinical hematological department of the Military Hospital Avicenna in Marrakech. We conducted a retrospective study over a period of 4 years from January, 1st 2012 to December, 31st 2015. We used an operating record, which includes epidemiological, clinical, biological, therapeutic and evolutionary criteria. During this period, we found that 70 cases were diagnosed and treated in the clinical hematological department of the HMA. We recorded 26 cases of multiple myeloma (37%), 23 cases of leukemia (33%), 19 cases of lymphoma (including 15 cases of non-Hodgkin lymphoma (21.4%) and 4 cases of Hodgkin lymphoma 5.7 %), 1 case of myelodysplastic syndrome (1.4%) and 1 case of polycythemia vera (1.4%). This work allowed us to note a significant increase in malignancies in this study. Hence the importance of raising the awareness of health professionals and raising awareness on a larger scale of the general population to improve the time of care and indirectly improve the prognosis of these diseases.
Keywords
Hematological Malignancies, Epidemiology, Biology
To cite this article
Mouhib Hanane, Zahir Hanane, Mouayche Ikhlas, Yahyaoui Hicham, Ait Ameur Mustapha, Chakour Mohammed, Hematological Malignancies: Epidemiological, Clinical, Biological, Therapeutic and Evolutionary Aspects, American Journal of Laboratory Medicine. Vol. 4, No. 1, 2019, pp. 19-23. doi: 10.11648/j.ajlm.20190401.13
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Mahboub. F. Z, Elkhattabi. W, L’youssfi. H, Aichaneet. A, Afif. H. Diagnostic positif et évolution des hémopathies malignes (à propos de 132 cas). Rev Mal Respir 2015; 32: A130-A130.
[2]
Delabesse E. Marqueurs génétiques des hémopathies. EMC- Biologiemédicale 2018; 13: 1-8.
[3]
Thachil. J, Bates. I. Approach to the Diagnosis and Classification oh Blood Cell Disorders. Practical Haematology 2017; 23: 497-510.
[4]
Questel. F. Hémopathies malignes d'origine professionnelle. Pathologie professionnelle et de l'environnement 2011; 6: 1-12.
[5]
RHAFEL. A. Bilan d’activité du service d’hématologie du CHU Mohammed VI (2009-2013). Thèse de doctorat en médecine, sous la direction du Pr. L. Mahmal, Marrakech, Faculté de médecine et de pharmacie, 2014; 223: 42-43.
[6]
Harif. M, Benider. A, BennaniOthmani. M. et al. Registre des cancers de la région du Grand Casablanca 2012; 88: 72-78.
[7]
Troussard. X, Duchenet. V, Cornet. E, Mouchel. D, Malet. M, Collignon. A. Epidémiologie des hémopathies malignes en Basse-Normandie. ‎Rev. épidémiol. santé publique 2009; 57: 151-158.
[8]
Fouquet. G, Guidez. S, Richez. V, Systchenko. T, Gruchet. C, Moya. N et all. Myélome multiple. EMC- Hématologie 2017; 12: 1-26.
[9]
Arnulf. B. Myélome multiple des os. Rev Prat 2013; 63: 101–8.
[10]
Laroche. M. Myélome multiple des os (maladie de Kahler). Rhumatologie pour le praticien 2018; 21: 257-263.
[11]
Tazi. M, Benjaafar. N, er-raki. A. Incidences des cancers à Rabat 2005; 84: 82-82.
[12]
Duployez. N, Decool. G, Preudhomme. C. Classification et facteurs pronostiques des leucémies aiguës. EMC- Hématologie 2018; 13: 1-14.
[13]
Opsomer. M.-A, Fagnoni. P, Bastie Pr. J.-N. Lymphomes. Pharmacie clinique pratique en oncologie 2016; 26: 211-211.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186